Oncology Clinical Trials in Bethesda, MD

As of June 2026, 221 paid clinical trials are recruiting for Oncology in Bethesda, Maryland. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

221 clinical trials for Oncology

·Clear filters·↓ Download CSV

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

for CLL

21 locations incl. Jonesboro

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06846671·Phase 3·Recruiting

Apply to this trial

Studying TAK-243 in Patients With Advanced Cancer

for Advanced Lymphoma

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06223542·Phase 1·Recruiting

Apply to this trial

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for Fallopian Tube Endometrioid Adenocarcinoma

Drug: Bevacizumab

658 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06580314·Phase 3·Recruiting

Apply to this trial

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for Hematopoietic and Lymphatic System Neoplasm

190 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: Female·Age: Up to 39

Code: NCT06513962·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for Diffuse Large B-Cell Lymphoma

Drug: Rituximab

42 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06717347·Phase 3·Recruiting

Apply to this trial

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

for Chronic Lymphocytic Leukemia

21 locations incl. Chandler

Sponsor: Loxo Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06588478·Phase 2·Recruiting

Apply to this trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

Drug: Rilvegostomig

74 locations incl. Tucson

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06692738·Phase 3·Recruiting

Apply to this trial

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

for Hematopoietic and Lymphatic System Neoplasm

76 locations incl. Mesa

Sponsor: Children's Oncology Group

Sex: All·Age: 15 - 20

Code: NCT06410209·Phase 2·Recruiting

Apply to this trial

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

for Astrocytoma

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 120

Code: NCT06344130·Phase 1·Recruiting

Apply to this trial

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

221 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06317649·Phase 2·Recruiting

Apply to this trial

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

211 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting

Apply to this trial

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

Drug: Venetoclax

167 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554393·Phase 2·Recruiting

Apply to this trial

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

for Leukemia, Lymphocytic, Chronic, B-Cell

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 120

Code: NCT06364423·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

for Chronic Lymphocytic Leukemia

Drug: Venetoclax

32 locations incl. Tucson

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06428019·Phase 3·Recruiting

Apply to this trial

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

for Hearing Loss

5 locations incl. Atlanta

Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD)

Sex: All·Age: 18 - 100

Code: NCT04915183·Phase 2·Recruiting

Apply to this trial

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

for Prostate Adenocarcinoma

7 locations incl. Chicago

Sponsor: Alessa Therapeutics Inc.

Sex: Male·Age: 21+

Code: NCT06257693·Phase 1·Recruiting

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

335 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

60 locations incl. Gilbert

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting

Apply to this trial

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

for Neuroendocrine Carcinomas

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 120

Code: NCT06041516·Phase 1·Recruiting

Apply to this trial

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

for Advanced Malignant Solid Neoplasm

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05691517·Phase 1·Recruiting

Apply to this trial

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

for Advanced Malignant Solid Neoplasm

Drug: Peposertib

6 locations incl. Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05687136·Phase 1·Recruiting

Apply to this trial

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

for Breast Cancer

53 locations incl. Anchorage

Sponsor: Exact Sciences Corporation

Sex: All·Age: 18+

Code: NCT06401421·Recruiting

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

Drug: Ruxolitinib

58 locations incl. Birmingham

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting

Apply to this trial

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

Drug: Etentamig

46 locations incl. Birmingham

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06158841·Phase 3·Recruiting

Apply to this trial

Vaginal Ecosystem and Network in the United States Study

for Bacterial Vaginosis

20 locations incl. Fullerton

Sponsor: Vaginal Biome Science

Sex: Female·Age: 18 - 89·Accepts healthy volunteers

Code: NCT06472765·Enrolling By Invitation

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

for Endometrial Cancer

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 120

Code: NCT06253494·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

for Malignant Female Reproductive System Neoplasm

186 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06126276·Phase 2·Recruiting

Apply to this trial

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

for Prostate Cancer

5 locations incl. Washington D.C.

Sponsor: Adam S. Kibel, MD

Sex: Male·Age: 40 - 69·Accepts healthy volunteers

Code: NCT06398639·Recruiting

Apply to this trial

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

Drug: Osimertinib

36 locations incl. Fountain Valley

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06350097·Phase 3·Recruiting

Apply to this trial

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

for Prostate Cancer

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: Male·Age: 18 - 120

Code: NCT06096870·Phase 2·Recruiting

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

156 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting

Apply to this trial

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

for Metastatic Colorectal Cancer

Drug: Retifanlimab

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 120

Code: NCT06149481·Phase 1, Phase 2·Recruiting

Apply to this trial

18F-Fluciclovine PET/CT in Multiple Myeloma

for Multiple Myeloma

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 120

Code: NCT06103838·Phase 2·Recruiting

Apply to this trial

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

for Glioma

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 120

Code: NCT06161519·Phase 1, Phase 2·Recruiting

Apply to this trial

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

for Advanced Solid Tumor

4 locations incl. Bethesda

Sponsor: Ankyra Therapeutics, Inc

Sex: All·Age: 18+

Code: NCT06171750·Phase 1·Recruiting

Apply to this trial

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

for Breast Cancer

79 locations incl. Phoenix

Sponsor: BriaCell Therapeutics Corporation

Sex: All·Age: 18+

Code: NCT06072612·Phase 3·Recruiting

Apply to this trial

Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer

for Prostate Cancer

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: Male·Age: 18+

Code: NCT04808427·Recruiting

Apply to this trial

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

for Prostatic Neoplasms

1 location in Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: Male·Age: 18 - 120

Code: NCT05616650·Phase 2·Recruiting

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1208 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting

Apply to this trial

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

for Advanced Malignant Solid Neoplasm

23 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05691491·Phase 1, Phase 2·Recruiting

Apply to this trial

Conditions in Oncology (Bethesda, MD)

Cancer (any)· 29 Solid tumor· 29 Prostate cancer· 23 Breast cancer· 21 Non-Hodgkin lymphoma· 20 Hematologic malignancy· 14 Melanoma· 14 Non-small cell lung cancer (NSCLC)· 13 Multiple myeloma· 12 Acute myeloid leukemia (AML)· 10 Myelodysplastic syndromes (MDS)· 10 Ovarian cancer· 9 Acute lymphoblastic leukemia· 9 Leukemia (other)· 9 Bladder cancer· 8 Chronic lymphocytic leukemia (CLL)· 8 Neuroendocrine tumors· 8 Colorectal cancer· 7 Kidney cancer· 7 Diffuse large B-cell lymphoma (DLBCL)· 7 Lung cancer· 6 Glioblastoma· 6 Small lymphocytic lymphoma· 6 Metastatic breast cancer· 5 Pancreatic cancer· 5 Liver cancer· 5 Biliary tract cancer· 5 Gastrointestinal cancer· 5 Neuroblastoma· 5 Mesothelioma· 5 Colon cancer· 4 Glioma· 4 Sarcoma· 4 Gastric cancer· 3 Cervical cancer· 3 Brain cancer· 3 Follicular lymphoma· 3 Mantle cell lymphoma· 3 Marginal zone lymphoma· 3 Head and neck cancer· 3 Thyroid cancer· 3 Metastatic colorectal cancer· 2 Endometrial cancer· 2 Uterine cancer· 2 Myelofibrosis· 2 Myeloproliferative neoplasm· 2 Hodgkin lymphoma· 2 Burkitt lymphoma· 2 Osteosarcoma· 2 Triple-negative breast cancer· 1 HER2-negative breast cancer· 1 Small cell lung cancer· 1 Rectal cancer· 1 Esophageal cancer· 1 Gastroesophageal junction cancer· 1 Metastatic prostate cancer· 1 Brain metastases· 1 Skin cancer· 1 Rhabdomyosarcoma· 1 Pediatric cancer· 1